Orexo AB
STO:ORX
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SE |
|
Orexo AB
STO:ORX
|
912.7m SEK |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
951.3B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
595.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
289.1B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
246.1B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.1B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
297.5B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.5B USD |
Loading...
|
Market Distribution
| Min | -5 565 412.8% |
| 30th Percentile | -5.3% |
| Median | 3% |
| 70th Percentile | 7.5% |
| Max | 12 228% |
Other Profitability Ratios
Orexo AB
Glance View
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 121 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Orexo AB is 2 458.8%, which is above its 3-year median of 125.2%.
Over the last 3 years, Orexo AB’s Net Margin has increased from -28.4% to 2 458.8%. During this period, it reached a low of -38.1% on Jun 30, 2025 and a high of 2 458.8% on Jan 31, 2026.
